Neoadjuvant Immunotherapy in Melanoma - The New Frontier

Clin Cancer Res. 2021 Aug 1;27(15):4133-4135. doi: 10.1158/1078-0432.CCR-21-1236. Epub 2021 Jun 3.

Abstract

Neoadjuvant immunotherapy is gathering pace, particularly in melanoma. A recent study of pembrolizumab and HDI not only further supports the safety and activity of neoadjuvant anti-PD-1 based immunotherapy but also highlights neoadjuvant therapy as a solid platform for drug development that is likely to become a standard-of-care in the near future.See related article by Najjar et al., p. 4195.

Publication types

  • Comment